September 28th, 2005

PRESS RELEASE

Clifton Mining Company Inc. (OTC : CFTN)
FOR RELEASE B September 28, 2005

ABL SALES CONTINUE TO INCREASE

OVERALL SALES INCREASE

American Biotech Labs (ABL), a private company (Clifton Mining Company owns over 24% of ABL) has just released general sales numbers ending August of 2005. ABL has completed sales for this year of over $1,700,000 as of the end of August.  In all of 2004 ABL had sales of $1,800,000.  It is anticipated that the fall months will be strong sales months for ABL as the company heads into the cold and flu season.

AT LEAST 30-40% GAINS

Management anticipates that overall sales for the year will show increases of at least
30 to 40% again this year, with store and doctor sales increasing approximately 100% from last year.

HOME RUNS ON THE HORIZON

The company continues to have a full line of activities that can have a substantial impact on sales in 2005 and even stronger in 2006.  Leading to possible exponential growth for the company and its shareholders.  Those activities include: a pending FDA application on the new SilGel product; the five marketing joint ventures that have been established with General Resonance moving forward; additional claims and uses for the ASAP-AGX-32™ product that have been filed for government approval, with more to be filed soon; continued positive military testing of the ABL products on Leishmaniasis; continued positive human studies on Malaria leading to widespread acceptance of the product as a treatment.  ABL also has a new product that is proving to be a success on the market, that being the new extra strength Health Max 30, a product that is sold exclusively to doctors and medical practitioners.

Clifton trades on the U.S. OTC: (CFTN).  For additional information, contact Dr. Ken Friedman, President at 303-642-0659, Keith Moeller Vice President at 801-756-1414 or see our website at www.cliftonmining.com

###

Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company=s business prospects and performance.